A new drug, ONO-1301, is a synthetic prostacyclin IP receptor agonist lacking the typical prostanoid structures, which contributes to the biological and chemical stability of this compound, resulting in long-lasting prostacyclin activity in vivo (11, 12) . In addition, ONO-1301 has a 3-pyridine radical, which exerts thromboxane A 2 synthase inhibitory activity, inducing an intrinsic prostaglandin I2 synthesispromoting effect to augment the IP receptor agonistic activity (13 147867-65-0, Nippon Fine Chemical), were dissolved, together with ONO-1301 (100 mg, Ono Pharmaceuticals, Osaka, Japan), in 20 g of t-butanol at 70 C.
The obtained solution was immediately frozen in dry ice/acetone, followed by freeze-drying for 17 h. 
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network in the border area was semi-quantitatively assessed by using immunohistology for the von Willebrand factor. The results showed that the von Willebrand factor-positive capillary network was better preserved in the myocardial interstitium of the ONO-NP group than in the myocardial interstitium of the other groups ( Figure 5A ). The results showed that PMNLs were markedly (B) Magnetic resonance imaging (11.7-T) displayed selective accumulation of gadolinium (Gd)-labeled liposomes in the ischemic area at 24 h after NP injection. I/R ¼ ischemia/reperfusion; NP ¼ nanoparticle.
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ONO-1301NPs Attenuate Myocardial I/R Injury accumulated in the infarct area in all groups but were rarely observed in the remote area in all groups.
In contrast, in the border area, significantly fewer Figure 6C ).
REDUCTION OF INFARCT SIZE BY ONO-1301NP
INJECTION. The area at risk of infarction and the infarct area were determined at 24 h after reperfusion by using Evans blue and triphenyltetrazolium chloride staining ( Figure 7A) Intravenously injected ONO-1301NPs selectively accumulated in the ischemic border area of the myocardium where microvasculature was impaired and exhibited enhanced permeability, as assessed by using MRI and confocal microscopy. As shown in the present study, NPs tended to remain in circulation, avoiding a pulmonary trap or renal excretion (17, 21) and, subsequently, effectively accumulated in the ischemic myocardium, particularly in the infarct border area; these findings contrasted with the results obtained when a solution form was administered. This #Significantly smaller than in the sham, vehicle, and ONO-solution groups. Abbreviations as in Figure 3 . ONO-1301NPs would thus be an ideal prostacyclin analogue for this pathology. Table 1 , Supplemental Figure 3 ). We therefore considered that 3 mg/kg was the optimum dose of ONO-1301. As a next step, further investigation is needed to explore the optimal dose and safety and to obtain a maximum benefit with minimum side effects in a large animal model. A second limitation of this study may be its relatively short observation period.
Given that the method uses a single injection after myocardial I/R, 24 h was the optimal point to investigate the efficacy of ONO-1301NPs. Further investigation is needed to determine long-term effects, with the manner of drug administration adjusted. Third, evaluation of additional ischemic circulating markers such as the FABP3, which has been shown to provide faster stress-to-recovery response, would be necessary to better understand the mechanism of recovery. TRANSLATIONAL OUTLOOK: Further investigation is needed to explore the optimal dose and safety of ONO-1301, with maximum pharmacological benefits and minimum adverse effects, and to establish a practical regimen for drug administration to achieve long-term effects.
